Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mutational analysis of the tyrosine phosphatome in colorectal cancers.
Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. Wang Z, et al. Among authors: sager j. Science. 2004 May 21;304(5674):1164-6. doi: 10.1126/science.1096096. Science. 2004. PMID: 15155950
PRL-3 expression in metastatic cancers.
Bardelli A, Saha S, Sager JA, Romans KE, Xin B, Markowitz SD, Lengauer C, Velculescu VE, Kinzler KW, Vogelstein B. Bardelli A, et al. Clin Cancer Res. 2003 Nov 15;9(15):5607-15. Clin Cancer Res. 2003. PMID: 14654542
PRL-3: a phosphatase for metastasis?
Sager JA, Benvenuti S, Bardelli A. Sager JA, et al. Cancer Biol Ther. 2004 Oct;3(10):952-3. doi: 10.4161/cbt.3.10.1115. Epub 2004 Oct 8. Cancer Biol Ther. 2004. PMID: 15467431
New paradigms for cancer drug discovery.
Sager JA, Lengauer C. Sager JA, et al. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S178-81. Cancer Biol Ther. 2003. PMID: 14508097 Review.
New paradigms for cancer drug discovery.
Sager JA, Lengauer C. Sager JA, et al. Cancer Biol Ther. 2003 Jul-Aug;2(4):452-5. doi: 10.4161/cbt.2.4.448. Cancer Biol Ther. 2003. PMID: 14508120 Review.
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. Camidge DR, et al. Among authors: sager j. Clin Cancer Res. 2010 Feb 15;16(4):1256-63. doi: 10.1158/1078-0432.CCR-09-1267. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145186 Clinical Trial.
A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
Plotnik D, Sager JE, Aryal M, Fanget MC, Peter A, Schmid MA, Cebrik D, Mogalian E, Boundy K, Yeh WW, Griffin P, Reyes M. Plotnik D, et al. Among authors: sager je. Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0127323. doi: 10.1128/aac.01273-23. Epub 2024 Feb 20. Antimicrob Agents Chemother. 2024. PMID: 38376227 Free PMC article. Clinical Trial.
201 results